Abstract：
:The absolute number of patients with lung cancer is rising as a result of our aging population. Until recently, clinicians have been reluctant to aggressively treat elderly patients with non-small-cell lung cancer (NSCLC) because of a lack of supportive data and concern for potential toxicity. Recently, evidence has emerged that suggests that, similar to younger patients, healthy elderly patients can benefit from therapy in all stages of NSCLC. This review will discuss the findings that indicate that chronologic age alone should not be a barrier to appropriate treatment for NSCLC, but consideration should be given to more important prognostic factors such as comorbidities and performance status.
journal_name
Clin Lung Cancerjournal_title
Clinical lung cancerauthors
Ng R,de Boer R,Green MDdoi
10.3816/CLC.2005.n.031keywords:
subject
Has Abstractpub_date
2005-11-01 00:00:00pages
168-74issue
3eissn
1525-7304issn
1938-0690pii
S1525-7304(11)70406-5journal_volume
7pub_type
杂志文章,评审abstract：:Historically, malignant pleural mesothelioma patients with potentially resectable disease have been treated with surgery and radiation alone. With improvements in systemic and intrapleural treatment options, a movement toward multi-modality therapy has become more common. Systemic treatment options largely consist of ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2009.n.005
更新日期：2009-01-01 00:00:00
abstract：:Viruses capable of inducing lysis of malignant cells through their replication process are known as "oncolytic" viruses. Clinical trials in oncology have been performed with oncolytic viruses for nearly fifty years. Both systemic and intratumoral routes of administration have been explored. Toxicity has generally been...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.1999.n.003
更新日期：1999-08-01 00:00:00
abstract：:Two cases of complications secondary to the use of microwave ablation (MWA) in non-small-cell lung cancer (NSCLC) are discussed herein. The first case involves a 62-year-old man with stage IB NSCLC who declined surgery and pursued MWA. Within 7 months, he had residual disease at the MWA treatment site, and surgery was...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2008.n.019
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:National costs of lung cancer care exceed $12 billion. We investigate the resource-savings benefit of a single-day thoracic oncology multidisciplinary clinic (MDC) in the diagnostic period prior to non-small-cell lung cancer (NSCLC) treatment. MATERIALS AND METHODS:From July 2007 to January 2015, patients w...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.02.010
更新日期：2019-07-01 00:00:00
abstract：INTRODUCTION:The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kir...
journal_title：Clinical lung cancer
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.cllc.2015.05.009
更新日期：2015-11-01 00:00:00
abstract：BACKGROUND:The safety and efficacy of platinum-based combination chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC) remains unclear. We conducted phase I and phase II trials of a combination of vinorelbine and carboplatin for patients ≥75 years of age and with advanced NSCLC. PATIENTS A...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.11.007
更新日期：2012-09-01 00:00:00
abstract：BACKGROUND:The primary objective of this study was to evaluate the association between radiation sensitivity of the lungs and candidate single nucleotide polymorphisms (SNP) in genes implicated in radiation-induced toxicity. METHODS:Patients with lung cancer who received radiation therapy (RT) had pre-RT and serial po...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2012.10.006
更新日期：2013-05-01 00:00:00
abstract：BACKGROUND:Pulmonary function tests are used to select patients with non-small-cell lung cancer (NSCLC) suitable for thoracic surgery. We studied the impact of pulmonary function tests on both quantitative (morbidity, mortality, and overall survival [OS]) and qualitative (quality of life [QOL]) outcomes of patients und...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2007.n.042
更新日期：2007-11-01 00:00:00
abstract：BACKGROUND:Evidence favoring a multidisciplinary team (MDT) approach in the treatment of lung cancer is scarce, especially in the United States. The purpose of the present investigation was to evaluate survival outcomes of lung cancer patients treated with an MDT compared with a traditional care model. PATIENTS AND ME...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2018.01.006
更新日期：2018-07-01 00:00:00
abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/clc.2001.n.017
更新日期：2001-08-01 00:00:00
abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.12.007
更新日期：2014-05-01 00:00:00
abstract：BACKGROUND:The immune checkpoint proteins programmed death-1/ligand (PD-1/PD-L1) play a critical role in immune escape of tumor cells. In models of epidermal growth factor receptor (EGFR)-driven non-small-cell lung cancer (NSCLC), EGFR signal upregulates PD-1/PD-L1. However, data on the clinical significance of PD1/PD-...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.02.002
更新日期：2015-09-01 00:00:00
abstract：:Conducting research in patients with non-small-cell lung cancer (NSCLC) is challenging, primarily because of low patient accrual rates resulting from patient-, physician-, protocol-, and healthcare system-related barriers. The Coalition of Cancer Cooperative Groups convened a 1-day program entitled Addressing the Curr...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2008.n.033
更新日期：2008-07-01 00:00:00
abstract：:Small-cell lung cancer (SCLC) is distinguished from non-small-cell lung cancer by its rapid growth and more frequent metastases. Although patients with SCLC are highly responsive to chemotherapy and radiation therapy, long-term prognosis remains poor, with relapse and disease recurrence occurring in almost all cases. ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2016.07.004
更新日期：2017-03-01 00:00:00
abstract：:This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...
journal_title：Clinical lung cancer
pub_type： 杂志文章,随机对照试验
doi：10.3816/CLC.2009.n.027
更新日期：2009-05-01 00:00:00
abstract：:The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations ...
journal_title：Clinical lung cancer
pub_type：
doi：10.3816/CLC.2009.n.044
更新日期：2009-09-01 00:00:00
abstract：INTRODUCTION:Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) in high-risk patients, but a minority of eligible people are screened. It is not clear whether knowledge of USPSTF recommendations among primary care physicians (PCP) affe...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.013
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.03.008
更新日期：2015-09-01 00:00:00
abstract：OBJECTIVE:Uncertainty exists regarding the optimal surveillance imaging schedule following definitive chemoradiation (CRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) with regards to both frequency and modality. We sought to document the clinical impact of frequent (at least every 4 months) surveillance ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.11.010
更新日期：2017-07-01 00:00:00
abstract：:Recent advances in cancer cell biology have led to the development of therapeutic agents that target pathways critical to the development and progression of disease. These so-called "targeted therapies" might offer patients a more tolerable alternative to traditional systemic chemotherapy that often achieves therapeut...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2006.n.037
更新日期：2006-09-01 00:00:00
abstract：BACKGROUND:Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS:From 2008 to 2011, 130 ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.01.006
更新日期：2016-09-01 00:00:00
abstract：INTRODUCTION:Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with p...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.02.017
更新日期：2020-05-01 00:00:00
abstract：INTRODUCTION:Malignant pleural mesothelioma (MPM) is a devastating neoplasm; however, some patients exhibit a good response to chemotherapy or multidisciplinary therapy, including surgery and chemotherapy. It is therefore important to discover the factors that can be used to select patients who will benefit from such t...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.01.008
更新日期：2017-07-01 00:00:00
abstract：BACKGROUND:In the present study we aimed to investigate whether the predominance of the lepidic component in tumors was associated with the outcome of postoperative adjuvant chemotherapy for stage I lung adenocarcinoma. PATIENTS AND METHODS:Charts for patients with pathological stage I lung adenocarcinoma were retrosp...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.11.015
更新日期：2016-09-01 00:00:00
abstract：:Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC). Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of met...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2010.n.046
更新日期：2010-09-01 00:00:00
abstract：BACKGROUND:The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties between mutant and wild-type EGFR have not been fully characterized. ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2018.03.011
更新日期：2018-09-01 00:00:00
abstract：INTRODUCTION:Computed tomography (CT)-guided lung biopsy is occasionally used for the lesions that were diagnosed as nonmalignant by transbronchial examination despite the fact that other clinical data suggested those as malignant. The purpose of this study is to evaluate the outcomes of CT fluoroscopy-guided cutting n...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2011.n.007
更新日期：2011-01-01 00:00:00
abstract：INTRODUCTION:Pneumonitis is one of the immune-related adverse events of programmed death 1 (PD-1) inhibitors that sometimes cause lethal outcomes. Although some recent reports have described PD-1 inhibitors as more effective in non-small-cell lung cancer (NSCLC) patients with immune-related adverse events than in those...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.cllc.2019.07.006
更新日期：2019-11-01 00:00:00
abstract：UNLABELLED:We retrospectively reviewed a total of 257 stage I to IIIa lung adenocarcinoma after resection, tested them for the epidermal growth factor receptor (EGFR) mutation, and analyzed the effect of perioperative treatment on survival. The results showed that in patients with an EGFR mutation, adjuvant EGFR-tyrosi...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.04.002
更新日期：2015-11-01 00:00:00
abstract：INTRODUCTION:For patients with T1 or T2 N0 M0 small-cell lung cancer (SCLC), lobectomy followed by chemotherapy is the standard of care. However, because of its tendency for early dissemination, patients are often treated with concurrent chemo-radiation without surgery. This study was conducted to evaluate the utilizat...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.07.013
更新日期：2020-03-01 00:00:00
